Goldman Sachs Group set a €80.00 ($95.24) target price on Morphosys (ETR:MOR) in a research note published on Monday. The firm currently has a neutral rating on the stock.

Other research analysts have also issued research reports about the stock. J P Morgan Chase & Co set a €62.00 ($73.81) price objective on shares of Morphosys and gave the stock a neutral rating in a research note on Friday, August 4th. Berenberg Bank set a €68.00 ($80.95) price target on shares of Morphosys and gave the company a buy rating in a research note on Wednesday, August 16th. Independent Research set a €77.00 ($91.67) price target on shares of Morphosys and gave the company a buy rating in a research note on Thursday, September 7th. Deutsche Bank set a €90.00 ($107.14) price target on shares of Morphosys and gave the company a buy rating in a research note on Thursday, September 7th. Finally, Oddo Bhf set a €76.00 ($90.48) price target on shares of Morphosys and gave the company a buy rating in a research note on Thursday, September 7th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. Morphosys currently has a consensus rating of Buy and a consensus target price of €82.25 ($97.92).

Morphosys (MOR) opened at €77.01 ($91.68) on Monday. Morphosys has a 52 week low of €40.10 ($47.74) and a 52 week high of €83.78 ($99.74).

ILLEGAL ACTIVITY WARNING: “Goldman Sachs Group Analysts Give Morphosys (MOR) a €80.00 Price Target” was published by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/goldman-sachs-group-analysts-give-morphosys-mor-a-80-00-price-target/1733921.html.

About Morphosys

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Analyst Recommendations for Morphosys (ETR:MOR)

Receive News & Ratings for Morphosys AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Morphosys AG and related companies with Analyst Ratings Network's FREE daily email newsletter.